Wen Lu

Wen Lu

Auto-generated profile, based on publicly available information

Wen Lu

Department of Chemistry, College of Arts & Sciences, Georgia State University, Atlanta, GA 30303, USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
ARAbhijeet Roy
Abhijeet Roy
HCHansam Cho
Hansam Cho
Kristin V LylesKristin V Lyles
Kristin V Lyles
WLWen Lu
Wen Lu
MLMing Luo
Ming Luo
LDLanying Du
Lanying Du
Zika virus (ZIKV) caused Zika outbreaks and continues to post threats to public health. ZIKV infection may cause congenital abnormalities during pregnancy and neurological manifestations in adults. The recurrent public health threat of Zika in various geographical areas demonstrates a need for the development of effective therapeutics. Currently, there are no approved therapies for Zika. ZIKV is a single-stranded, positive-sense RNA virus, whose genome encodes three structural proteins and seven non-structural proteins. The surface envelope (E) protein is essential for host–cell recognition and viral entry; therefore, inhibition of E-mediated viral entry is a key strategy underlying antiviral treatments. Here, molecular docking-based virtual screening was used to screen small-molecule compound libraries to identify potential ZIKV entry inhibitors. Among the compounds identified, Pyrimidine-Der1 exhibited efficient inhibition of reporter ZIKV infection. The microscale thermophoresis assay confirmed its binding with the ZIKV E protein. This compound has effective inhibition of authentic ZIKV infection in a plaque inhibition assay against R103451, PAN2016, and FLR human strains (IC50: ~3–5 μM). Additionally, it efficiently inhibited ZIKV infection at viral entry and fusion steps of the virus life cycle in a time-of-addition assay. Overall, Pyrimidine-Der1 is a promising ZIKV entry inhibitor, warranting further optimization and evaluation.

17 December 2025 in ChemRxiv
Verified
Preprint
Open access
PDF file
SKShameer M. Kondengadan
Shameer M. Kondengadan
SBShubham Bansal
Shubham Bansal
WLWen Lu
Wen Lu
MCManjusha Roy Choudhury
Manjusha Roy Choudhury
Binghe WangBinghe Wang
Binghe Wang
Because of the association of various pathological conditions with the over-production of reactive oxygen species (ROS), there is a strong interest in ROS-sensitive linker chemistry for drug delivery and other applications. Most ROS-sensitive cleavable linkers rely on their broad reactivity toward all ROS including the least reactive ROS, hydrogen peroxide, and highly reactive oxygen species (hROS) such as hypochlorite, peroxynitrite, and hydroxy radical. However, individual ROS has very specialized functions and unique roles in various pathologies. Therefore, there is a need for species-selective activation chemistry for drug delivery applications. OCl- is the second most abundant ROS and primarily produced in response to infection and/or inflammation by certain immune cells that express myeloperoxidase (MPO). We herein describe a novel hROS-selective prodrug approach through a OCl--initiated Cascade Reaction with Kinetic Tunability (CReKT) for drug release. Specifically, ClO- oxidation of a phenylthioether is used to create a cleavable event, via enhancing the nucleophilicity of the S-connected carbon for condensation-based payload release. The reactivity of the S-connected carbon is further augmented by tethering to an electron-withdrawing group (EWG) and by creating synergy with proximity effects. Tunability of release kinetics can be achieved by varying the EWG, substitution on the phenyl ring, and entropic factors. This approach has four key features: (1) stable prodrugs, (2) selectivity for hypochlorite-activation, (3) tunability in release kinetics, and (4) free of labile metal- or boron-based groups. This approach affords new tools and sets a new direction in designing species-selective ROS-sensitive prodrugs.

Verified
Journal Article
Open access
PDF file
RMRabeya Jafrin Mow
Rabeya Jafrin Mow
XSXiaodi Shi
Xiaodi Shi
WLWen Lu
Wen Lu
SWSiming Wang
Siming Wang
Didier MerlinDidier Merlin
Didier Merlin
CYChunhua Yang
Chunhua Yang
Ulcerative colitis (UC) is a chronic inflammatory disorder of the colon characterized by dysregulated mucosal immunity and progressive epithelial injury. Upadacitinib (UPA), a selective Janus kinase 1 (JAK1) inhibitor, has demonstrated clinical efficacy in UC, but its therapeutic application is often constrained by adverse effects arising from systemic drug exposure. This underscores the need for advanced, site-specific delivery systems that enhance local efficacy while minimizing systemic toxicity. Here, we developed a colon-targeted natural lipid nanoparticle formulation of UPA (UPA-nLNP) to improve therapeutic performance and safety. UPA-nLNP was prepared by thin-film hydration using digalactosyldiacylglycerol (DGDG), monogalactosyldiacylglycerol (MGDG), and phosphatidic acid (PA), mimicking the lipid composition of ginger-derived exosomal particles, and was characterized for particle size, surface charge, and encapsulation efficiency. The formulation exhibited excellent mucus-penetrating capability and was evaluated in a dextran sulfate sodium (DSS)-induced acute colitis model in C57BL/6 mice following oral administration (5 mg/kg). Pharmacokinetic analysis demonstrated increased colonic accumulation with reduced systemic exposure compared to free UPA. Treatment with UPA-nLNP improved body weight recovery, reduced disease biomarkers, and suppressed key proinflammatory cytokines in the colon, with no evidence of systemic toxicity. This innovative strategy holds strong potential to enhance the clinical utility of JAK1 inhibitors by providing a safer and more effective therapeutic approach for ulcerative colitis.